FDA
-
-
-
-
-
-
-
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
-
-
-
-
-
-
-
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiati
-
-
-
-
-
-
-
AtaiBeckley reports positive trial results for social anxiety drug
-
-
-
-
-
-
-
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on atai Life Sciences N.V (ATAI)
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Announces $50M Private Placement
-
-
-
-
-
-
-
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
-
326,130 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

